Becton Dickinson & Co (BDX) is fairly valued and West Pharmaceutical Services Inc (WST) is overvalued.
Against our estimates of intrinsic value, BDX trades at the wider discount: a margin of safety of +4%, against -256% for WST.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 7.0% (average of 3 methods) values the shares at $190.08; the price of $183.00 is 4% below that value, and 83% of that value comes from beyond year five.
Leak Score 34/100 on 9 of 12 signals
Discounting its cash flows at 10.4% (average of 3 methods) values the shares at $104.26; the price of $371.09 is 256% above that value, and 71% of that value comes from beyond year five.
Leak Score 61/100 on 10 of 12 signals
| Metric | BDX | WST |
|---|---|---|
| Verdict | Fairly valued | Overvalued |
| Price | $183.00 | $371.09 |
| Intrinsic value | $190.08 | $104.26 |
| Margin of safety | +4% | -256% |
| Leak Score | 34/100 (9/12) | 61/100 (10/12) |
| Market cap | $49.8B | $26.1B |
| Revenue growth, 5 years | 6.3% | 7.4% |
| Operating margin | 14.5% | 22.0% |
| Net margin | 4.5% | 17.0% |
| Return on equity | 5.2% | 19.1% |
| Debt to equity | 0.69 | 0.11 |
| P/E | 55.2x | 47.4x |
| Forward P/E | 13.8x | 37.1x |
| P/B | 2.0x | 8.7x |
| Dividend yield | 2.2% | 0.2% |